Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Filiz Yucebay, PharmD, BCPS, BCOP, Ashleigh Keiter, MS, Qiuhong Zhao, MS, Alison Neal, Nita Williams, Nidhi Sharma, PhD, Francesca Cottini, MD, Maria Chaudhry, MD, Ashley Rosko, MD, Don M. Benson, Jr., MD PhD, Yvonne A. Efebera, MD MPH, Naresh Bumma, MD, Abdullah Khan, MBBS, MSc, Srinivas Devarakonda, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141105

Published: 2020

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Jihad Aljabban, MMSc, BA, Nabeal Aljabban, BS, Mohamad Mukhtar, BS, Saad Syed, BS, Ross Wanner, BS, Francesca Cottini, MD, Tiffany Hughes, BS, PhD, Kareem Saleh, BS, Evan C Catton, Taylor Gonzalez, Maryam Panahiazar, PhD, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2018-99-112265

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Taylor Gonzalez, Evan C Catton, Ashley E. Rosko, MD, Yvonne Efebera, MD, Maria Chaudhry, MD, Francesca Cottini, MD, Bethany L Mundy-Bosse, PhD, Tiffany Hughes, BS, PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2018-99-117465

Published: 2018

Journal Articles

Targeting Replicative Stress to Treat Hematological Disorders

Francesca Cottini, MD, Giovanni Tonon, MD PhD, Teru Hideshima, MD, PhD, Paul G. Richardson, MD, Kenneth C Anderson

Blood (2015) 126 (23): 2419.

https://doi.org/10.1182/blood.V126.23.2419.2419

Published: 2015

Journal Articles

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Rikio Suzuki, MD, PhD, Teru Hideshima, MD, PhD, Shuichi Ohkubo, PhD, Naoya Mimura, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Shohei Kikuchi, MD, PhD, Diana D. Cirstea, Francesca Cottini, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Teruhiro Utsugi, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4429.

https://doi.org/10.1182/blood.V122.21.4429.4429

Published: 2013

Journal Articles

The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma

Francesca Cottini, MD, Teru Hideshima, MD, PhD, Giovanni Tonon, MD, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3114.

https://doi.org/10.1182/blood.V122.21.3114.3114

Published: 2013

Journal Articles

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Sun-Young Kong, MD, PhD, Yosef Landesman, PhD, Jana Jakubikova, PhD, Michael A. Sellitto, Antonia Cagnetta, MD, Michele Cea, MD, Michelle C. Chen, Francesca Cottini, MD, Douglas W. McMillin, PhD, Chirag Acharya, MD, William Senapedis, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, Jean-Richard Saint-Martin, BS, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2011) 118 (21): 2913.

https://doi.org/10.1182/blood.V118.21.2913.2913

Published: 2011

Journal Articles

Targeting NAD + Salvage Pathway Induces Autophagy in Multiple Myeloma Cells

Michele Cea, MD, Antonia Cagnetta, MD, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Sun-Young Kong, MD, PhD, Teresa Calimeri, M.D., Francesca Cottini, MD, Jana Jakubikova, PhD, Alessio Nencioni, Marco Gobbi, MD, Franco Patrone, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2920.

https://doi.org/10.1182/blood.V118.21.2920.2920

Published: 2011

Journal Articles

CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL

Paolo Ghia, MD, PhD, Claudia Fazi, PhD, Lorenza Pecciarini, PhD, Lydia Scarfò, MD, Francesca Cottini, MD, Antonis Dagklis, PhD, Agnieszka Janus, MD, Cristina Scielzo, Cinzia Sala, PhD, Daniela Toniolo, PhD, Federico Caligaris-Cappio, MD

Blood (2010) 116 (21): 2440.

https://doi.org/10.1182/blood.V116.21.2440.2440

Published: 2010

NARROW

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Targeting Replicative Stress to Treat Hematological Disorders

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Targeting NAD + Salvage Pathway Induces Autophagy in Multiple Myeloma Cells

CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only